|
AFC-HD AMS Life Science Co., Ltd. is a Japanese conglomerate operating primarily in the healthcare and pharmaceutical sectors. The company's core business involves the contract manufacturing and OEM production of health foods, supplements, and cosmetics, supported by research and development capabilities. Its pharmaceutical segment focuses on the manufacturing and sales of medical, general, and generic drugs, including traditional Chinese medicine. The group also operates a diversified portfolio of businesses including department stores, food and beverage services, tourism, and real estate management. Key subsidiaries include Honzo Pharmaceutical for drug production, Nihon Yobou Ika Kenkyusho for health product R&D, and Saikaya for department store operations. The company serves domestic and international markets, with specific subsidiaries handling sales and raw material procurement in China. It maintains GMP-certified facilities for health food production and offers total production management from planning to final product delivery. Summarised from the annual report, fiscal year ended Aug 2025 |
Industry Drug Manufacturers - General | Homepage ams-life.com |
| Sector Healthcare | IR page — | |
|
Tags
contract manufacturing, health foods, cosmetics, traditional chinese medicine, generic drugs, department stores, food and beverage, real estate management, tourism, oem production, Honzo Pharmaceutical, Nihon Yobou Ika Kenkyusho, Saikaya, Kengou TV, Hangzhou Yongyuan'ai Biotechnology, Shanghai Yongyuan'ai Biotechnology, Aifuxi (Chongqing) Biotechnology, Alpha Trend, Saikaya Yuunokai, Nasubi, Fujitaka & Partners, FSC, AFC Smile Real Estate, AFC Smile Plus, AFC Kentaku, New World Entertainment, Rabbit Express, Rabbit Travel, AFC Tourism, 5SPRO Joint Stock Company
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | ¥ 12.347B |
| Market cap (USD) | $ 77.167M |
| P/E | 10.23 |
| PEG | 3.65 |
| P/BV | 0.75 |
| P/S | 0.36 |
| P/OCF | 7.36 |
| P/FCF | -7.05 |
| Dividend yield | 4.7% |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | 7.6% |
| ROI | 7.3% |
| ROIC | 11.2% |
| Profit margin | 3.5% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | No |
| Revenue up 3y | Yes |
| Revenue up 5y | Yes |
| Earnings growth 3y (net profit CAGR) | 2.8% |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | No |
| Buying back stock | No |
| Diluting (TTM) | Yes |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 0 |
| Quality score | 27.8% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 34.324B | 32.655B | 30.185B | 25.579B | 22.997B | 22.368B | 15.819B | 16.253B | 15.796B | 15.142B | 14.631B | 14.415B | 13.728B | 14.366B | 14.795B |
| Net profit | 1.198B | 1.449B | 1.252B | 1.103B | 735.353M | 1.496B | 676.683M | 783.292M | 736.68M | 465.893M | 489.6M | 605.503M | 282.979M | 572.392M | 569.044M |
| Free cash flow | — | -1.752B | -1.867B | -1.074B | 534.446M | 2.091B | 917.745M | 585.143M | 672.299M | -326.327M | 691.169M | 599.19M | — | — | — |
| Figure | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Share price | 873 | 864.67 | 832.59 | 792.95 | 768.67 | 1.148K | 674.45 | 651.33 | 716.64 | 823.49 | 809.43 | 791.04 | 701.91 | 698.31 | 667.8 |
| Price performance 12m | 0.01 | 0.04 | 0.05 | 0.03 | -0.33 | 0.7 | 0.04 | -0.09 | -0.13 | 0.02 | 0.02 | 0.13 | 0.01 | 0.05 | — |
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Aug 2017 | Aug 2018 | Aug 2019 | Aug 2020 | Aug 2021 | Aug 2022 | Aug 2023 | Aug 2024 | Aug 2025 | Aug 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Balance sheet detail | ||||||||||
| Trade receivables (JPY) | 2.05B | 2.06B | 2.16B | 2.19B | 2.24B | 2.58B | 2.84B | 2.81B | 2.93B | 3.29B |
| ↳ YoY growth | +8.4% | +0.2% | +5.1% | +1.2% | +2.5% | +14.9% | +10.2% | -1.1% | +4.2% | +12.1% |
| ↳ 5y CAGR | +0.9% | +3.4% | +4.7% | +6.7% | +5.4% | +6.0% | +7.9% | |||
| Borrowings, current (JPY) | 4.59B | 2.93B | 3.59B | 2.87B | 4.99B | 7B | 8.22B | 9.6B | 18.4B | 18.8B |
| Borrowings, non-current (JPY) | 505M | 1.32B | 486M | 1.08B | 9.69B | 10.1B | 11.3B | 13.3B | 5.48B | 4.61B |
| Bonds payable (JPY) | 171M | 60M | — | — | — | — | — | — | — | — |
| Cash and deposits (JPY) | 3.39B | 4.08B | 4.44B | 4.73B | 9.22B | 10.4B | 11.2B | 12.2B | 11.3B | 9.76B |
| Intangible assets (JPY) | 103M | 95.3M | 149M | 163M | 1.65B | 1.46B | 1.38B | 2.52B | 2.02B | 1.54B |
| Net debt (borrowings + leases - cash) (JPY) | 1.71B | 171M | -358M | -777M | 5.46B | 6.76B | 8.36B | 10.7B | 12.6B | 13.6B |
| Cash flow detail | ||||||||||
| Operating cash flow (JPY) | 526M | 1.22B | 1.13B | 1.3B | 2.58B | 1.49B | 865M | 1.54B | 1.79B | 1.68B |
| Purchases of property, plant and equipment (JPY) | -852M | -549M | -547M | -381M | -492M | -958M | -1.94B | -3.41B | -3.54B | -2.4B |
| Change in receivables (cash effect) (JPY) | -159M | -3.92M | -106M | -26.3M | 294M | -333M | -206M | 157M | -147M | -340M |
| Change in inventories (cash effect) (JPY) | -172M | -253M | -12.7M | -172M | -361M | 123M | -633M | -1.43B | -890M | -629M |
| Change in payables (cash effect) (JPY) | 62.3M | 121M | -191M | 195M | -84.9M | 447M | -211M | 278M | 52M | -376M |
| Dividends paid (cash effect) (JPY) | -181M | -181M | -280M | -350M | -313M | -422M | -385M | -419M | -434M | -514M |
| Share buybacks (cash effect) (JPY) | -54,000 | — | — | -29,000 | -153M | -289M | -79.6M | — | -13.2M | — |
| Interest paid (cash effect) (JPY) | -65M | -56.7M | -34.1M | -28.7M | -31.1M | -58.4M | -58.8M | -97.8M | -193M | -289M |
| Income taxes paid (cash effect) (JPY) | -256M | -181M | -263M | -381M | -322M | -994M | -283M | -576M | -798M | -831M |
| Operating cash flow before change in receivables (JPY) | 684M | 1.23B | 1.24B | 1.33B | 2.29B | 1.83B | 1.07B | 1.38B | 1.93B | 2.02B |
| Free cash flow (OCF - PPE - intangibles) (JPY) | -326M | 672M | 585M | 918M | 2.09B | 534M | -1.07B | -1.87B | -1.75B | -726M |
| Income detail | ||||||||||
| Research and development expense (JPY) | 116M | 139M | 157M | 166M | 164M | 153M | 145M | 148M | 143M | — |
| ↳ 5y CAGR | +8.9% | +8.2% | +5.7% | +0.8% | -1.1% | -3.0% | ||||
| Total comprehensive income (JPY) | 473M | 718M | 738M | 706M | 1.52B | 827M | 1.14B | 1.14B | 1.58B | 1.29B |
| Comprehensive income to owners (JPY) | 473M | 718M | 738M | 706M | 1.52B | 825M | 1.14B | 1.15B | 1.54B | 1.28B |
| Provision for credit losses (JPY) | 4.55M | 4.9M | 19.9M | 40.9M | — | — | — | 4.6M | -1.19M | — |
| Credit cost ratio (credit losses / average receivables) (%) | 0.2% | 0.2% | 0.9% | 1.9% | — | — | — | 0.2% | 0.0% | — |
| Segments | ||||||||||
| Department Store Business · Segment revenue (JPY) | — | — | — | — | 3.21B | 4.7B | 5.2B | 4.95B | 4.62B | 4.58B |
| ↳ YoY growth | +46.6% | +10.7% | -4.9% | -6.6% | -0.9% | |||||
| Department Store Business · Segment operating income (JPY) | — | — | — | — | -118M | -249M | 94.6M | 33.4M | 61.8M | 64.9M |
| Food Service Business · Segment revenue (JPY) | — | — | — | — | 158M | 921M | 1.48B | 2.18B | 2.41B | 2.6B |
| ↳ YoY growth | +484.3% | +61.1% | +46.9% | +10.6% | +8.0% | |||||
| Food Service Business · Segment operating income (JPY) | — | — | — | — | -87.2M | -355M | -119M | -71M | -74.9M | -16.5M |
| Real Estate And Consignment Business · Segment revenue (JPY) | — | — | — | — | — | — | 1.3B | 1.95B | 2.71B | 2.86B |
| ↳ YoY growth | +50.5% | +38.9% | +5.6% | |||||||
| Real Estate And Consignment Business · Segment operating income (JPY) | — | — | — | — | — | — | 64.8M | -268M | 16.6M | 29.4M |
| Reported | Nov 28, 2017 | Nov 27, 2018 | Nov 26, 2019 | Nov 25, 2020 | Nov 25, 2021 | Nov 30, 2022 | Nov 27, 2024 | Nov 26, 2025 | Nov 26, 2025 | Oct 15, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpTimely disclosures published on TDnet, newest first, titles as filed in Japanese. The link opens the disclosure on TDnet. Filings with EDINET (periodic reports, extraordinary reports, offerings, holding and buy-back reports), newest first, titles as filed in Japanese. The link opens the filing on EDINET.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding AFC-HD AMS Life Science Co., Ltd.
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.